Global Adalimumab Biosimilar

Adalimumab Biosimilar Comprehensive Study by Type (Exemptia, Adalirel, Cipleumab, Others), Application (Psoriatic Arthritis, Rheumatoid Arthritis, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2030

Adalimumab Biosimilar Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Adalimumab Biosimilar?
A biosimilar is a type of biologic equivalent to that of pre-approved biologics. Adalimumab was the first fully human monoclonal antibody approved by the U.S. Food and Drug Administration in December 2002. A biosimilar is a biotherapeutic that is clinically highly similar to an approved original biologic in terms of active ingredients and has no meaningful differences in efficacy and safety. Biosimilars are also called as follow-on biologics or subsequent entry biologics. Adalimumab is a medication used to treat psoriatic arthritis, rheumatoid arthritis, and many other diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia- Pacific
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledAET BioTech (Germany), Amgen (United States), Boehringer Ingelheim (Germany), Coherus Biosciences (United States), Fujifilm Kyowa Kirin Biologics (Japan), LG Life Sciences (South Korea), Momenta Pharmaceuticals (United States), Oncobiologics (New Jersey), Pfizer (United States) and Samsung Bioepsis (United States)


The study covers a detailed analysis segmented by key business segments i.e. by type (Exemptia, Adalirel, Cipleumab and Others) , by application (Psoriatic Arthritis, Rheumatoid Arthritis and Other) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Adalimumab Biosimilar market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Adalimumab Biosimilar market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are AET BioTech (Germany), Amgen (United States), Boehringer Ingelheim (Germany), Coherus Biosciences (United States), Fujifilm Kyowa Kirin Biologics (Japan), LG Life Sciences (South Korea), Momenta Pharmaceuticals (United States), Oncobiologics (New Jersey), Pfizer (United States) and Samsung Bioepsis (United States).

Market Overview:
In July 2023, Biocon Biologics, a subsidiary of Biocon, has launched a biosimilar version of AbbVie's top-selling biologic Humira (generically called adalimumab) in the US market under brand name HULIO.

The Abacavir market is characterized by the presence of established global players. The market is competitive and the vendors are increasingly competing against each other based on factors such as aggressive pricing, product differentiation, capital support for a product, and distribution partnerships, and research advancements.

Influencing Trend:
Rise in the Approvals of the New Biosimilars and High Investment in the Research and Manufacturing of the New Adalimumab Biosimilars

Market Growth Drivers:
Rise in the Geriatric Population and Increasing Prevalence of Rheumatoid Arthritis

Challenges:
Growing Concern Regarding development Complexities

Restraints:
High Cost Associated with Adalimumab Biosimilar

Opportunities:
Growing Government Healthcare Expenditure in Developing Courtiers

Key highlights of the Global Adalimumab Biosimilar market Study:
• CAGR of the market during the forecast period 2023-2030
• In-depth information on growth factors that will accelerate the Adalimumab Biosimilar market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Adalimumab Biosimilar market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Adalimumab Biosimilar Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Adalimumab Biosimilar market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Adalimumab Biosimilar market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Government Regulatory Bodies, Private Research Organizations, Government Research Organizations, Industry Associations and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Exemptia
  • Adalirel
  • Cipleumab
  • Others
By Application
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Other
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Geriatric Population
      • 3.2.2. Increasing Prevalence of Rheumatoid Arthritis
    • 3.3. Market Challenges
      • 3.3.1. Growing Concern Regarding development Complexities
    • 3.4. Market Trends
      • 3.4.1. Rise in the Approvals of the New Biosimilars
      • 3.4.2. High Investment in the Research and Manufacturing of the New Adalimumab Biosimilars
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adalimumab Biosimilar, by Type, Application, Distribution Channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Adalimumab Biosimilar (Value)
      • 5.2.1. Global Adalimumab Biosimilar by: Type (Value)
        • 5.2.1.1. Exemptia
        • 5.2.1.2. Adalirel
        • 5.2.1.3. Cipleumab
        • 5.2.1.4. Others
      • 5.2.2. Global Adalimumab Biosimilar by: Application (Value)
        • 5.2.2.1. Psoriatic Arthritis
        • 5.2.2.2. Rheumatoid Arthritis
        • 5.2.2.3. Other
      • 5.2.3. Global Adalimumab Biosimilar by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
      • 5.2.4. Global Adalimumab Biosimilar Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Adalimumab Biosimilar (Volume)
      • 5.3.1. Global Adalimumab Biosimilar by: Type (Volume)
        • 5.3.1.1. Exemptia
        • 5.3.1.2. Adalirel
        • 5.3.1.3. Cipleumab
        • 5.3.1.4. Others
      • 5.3.2. Global Adalimumab Biosimilar by: Application (Volume)
        • 5.3.2.1. Psoriatic Arthritis
        • 5.3.2.2. Rheumatoid Arthritis
        • 5.3.2.3. Other
      • 5.3.3. Global Adalimumab Biosimilar by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacy
        • 5.3.3.2. Retail Pharmacy
        • 5.3.3.3. Online Pharmacy
      • 5.3.4. Global Adalimumab Biosimilar Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Adalimumab Biosimilar (Price)
      • 5.4.1. Global Adalimumab Biosimilar by: Type (Price)
  • 6. Adalimumab Biosimilar: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AET BioTech (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Coherus Biosciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fujifilm Kyowa Kirin Biologics (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LG Life Sciences (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Momenta Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oncobiologics (New Jersey)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Samsung Bioepsis (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Adalimumab Biosimilar Sale, by Type, Application, Distribution Channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Adalimumab Biosimilar (Value)
      • 7.2.1. Global Adalimumab Biosimilar by: Type (Value)
        • 7.2.1.1. Exemptia
        • 7.2.1.2. Adalirel
        • 7.2.1.3. Cipleumab
        • 7.2.1.4. Others
      • 7.2.2. Global Adalimumab Biosimilar by: Application (Value)
        • 7.2.2.1. Psoriatic Arthritis
        • 7.2.2.2. Rheumatoid Arthritis
        • 7.2.2.3. Other
      • 7.2.3. Global Adalimumab Biosimilar by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
      • 7.2.4. Global Adalimumab Biosimilar Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Adalimumab Biosimilar (Volume)
      • 7.3.1. Global Adalimumab Biosimilar by: Type (Volume)
        • 7.3.1.1. Exemptia
        • 7.3.1.2. Adalirel
        • 7.3.1.3. Cipleumab
        • 7.3.1.4. Others
      • 7.3.2. Global Adalimumab Biosimilar by: Application (Volume)
        • 7.3.2.1. Psoriatic Arthritis
        • 7.3.2.2. Rheumatoid Arthritis
        • 7.3.2.3. Other
      • 7.3.3. Global Adalimumab Biosimilar by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacy
        • 7.3.3.2. Retail Pharmacy
        • 7.3.3.3. Online Pharmacy
      • 7.3.4. Global Adalimumab Biosimilar Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Adalimumab Biosimilar (Price)
      • 7.4.1. Global Adalimumab Biosimilar by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adalimumab Biosimilar: by Type(USD Million)
  • Table 2. Adalimumab Biosimilar Exemptia , by Region USD Million (2018-2023)
  • Table 3. Adalimumab Biosimilar Adalirel , by Region USD Million (2018-2023)
  • Table 4. Adalimumab Biosimilar Cipleumab , by Region USD Million (2018-2023)
  • Table 5. Adalimumab Biosimilar Others , by Region USD Million (2018-2023)
  • Table 6. Adalimumab Biosimilar: by Application(USD Million)
  • Table 7. Adalimumab Biosimilar Psoriatic Arthritis , by Region USD Million (2018-2023)
  • Table 8. Adalimumab Biosimilar Rheumatoid Arthritis , by Region USD Million (2018-2023)
  • Table 9. Adalimumab Biosimilar Other , by Region USD Million (2018-2023)
  • Table 10. Adalimumab Biosimilar: by Distribution Channel(USD Million)
  • Table 11. Adalimumab Biosimilar Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Adalimumab Biosimilar Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Adalimumab Biosimilar Online Pharmacy , by Region USD Million (2018-2023)
  • Table 14. South America Adalimumab Biosimilar, by Country USD Million (2018-2023)
  • Table 15. South America Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 16. South America Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 17. South America Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 18. Brazil Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 19. Brazil Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 20. Brazil Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 21. Argentina Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 22. Argentina Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 23. Argentina Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 24. Rest of South America Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 27. Asia Pacific Adalimumab Biosimilar, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 31. China Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 32. China Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 33. China Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 34. Japan Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 35. Japan Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 36. Japan Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 37. India Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 38. India Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 39. India Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 40. South Korea Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 41. South Korea Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 42. South Korea Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 43. Taiwan Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 44. Taiwan Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 45. Taiwan Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 46. Australia Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 47. Australia Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 48. Australia Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 52. Europe Adalimumab Biosimilar, by Country USD Million (2018-2023)
  • Table 53. Europe Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 54. Europe Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 55. Europe Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 56. Germany Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 57. Germany Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 58. Germany Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 59. France Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 60. France Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 61. France Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 62. Italy Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 63. Italy Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 64. Italy Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 65. United Kingdom Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 68. Netherlands Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 69. Netherlands Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 70. Netherlands Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Europe Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 74. MEA Adalimumab Biosimilar, by Country USD Million (2018-2023)
  • Table 75. MEA Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 76. MEA Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 77. MEA Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 78. Middle East Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 79. Middle East Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 80. Middle East Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 81. Africa Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 82. Africa Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 83. Africa Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 84. North America Adalimumab Biosimilar, by Country USD Million (2018-2023)
  • Table 85. North America Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 86. North America Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 87. North America Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 88. United States Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 89. United States Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 90. United States Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 91. Canada Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 92. Canada Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 93. Canada Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 94. Mexico Adalimumab Biosimilar, by Type USD Million (2018-2023)
  • Table 95. Mexico Adalimumab Biosimilar, by Application USD Million (2018-2023)
  • Table 96. Mexico Adalimumab Biosimilar, by Distribution Channel USD Million (2018-2023)
  • Table 97. Adalimumab Biosimilar Sales: by Type(K Units)
  • Table 98. Adalimumab Biosimilar Sales Exemptia , by Region K Units (2018-2023)
  • Table 99. Adalimumab Biosimilar Sales Adalirel , by Region K Units (2018-2023)
  • Table 100. Adalimumab Biosimilar Sales Cipleumab , by Region K Units (2018-2023)
  • Table 101. Adalimumab Biosimilar Sales Others , by Region K Units (2018-2023)
  • Table 102. Adalimumab Biosimilar Sales: by Application(K Units)
  • Table 103. Adalimumab Biosimilar Sales Psoriatic Arthritis , by Region K Units (2018-2023)
  • Table 104. Adalimumab Biosimilar Sales Rheumatoid Arthritis , by Region K Units (2018-2023)
  • Table 105. Adalimumab Biosimilar Sales Other , by Region K Units (2018-2023)
  • Table 106. Adalimumab Biosimilar Sales: by Distribution Channel(K Units)
  • Table 107. Adalimumab Biosimilar Sales Hospital Pharmacy , by Region K Units (2018-2023)
  • Table 108. Adalimumab Biosimilar Sales Retail Pharmacy , by Region K Units (2018-2023)
  • Table 109. Adalimumab Biosimilar Sales Online Pharmacy , by Region K Units (2018-2023)
  • Table 110. South America Adalimumab Biosimilar Sales, by Country K Units (2018-2023)
  • Table 111. South America Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 112. South America Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 113. South America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 114. Brazil Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 115. Brazil Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 116. Brazil Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 117. Argentina Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 118. Argentina Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 119. Argentina Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 120. Rest of South America Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 121. Rest of South America Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 122. Rest of South America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 123. Asia Pacific Adalimumab Biosimilar Sales, by Country K Units (2018-2023)
  • Table 124. Asia Pacific Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 125. Asia Pacific Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 126. Asia Pacific Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 127. China Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 128. China Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 129. China Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 130. Japan Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 131. Japan Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 132. Japan Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 133. India Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 134. India Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 135. India Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 136. South Korea Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 137. South Korea Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 138. South Korea Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 139. Taiwan Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 140. Taiwan Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 141. Taiwan Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 142. Australia Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 143. Australia Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 144. Australia Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 145. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 146. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 147. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 148. Europe Adalimumab Biosimilar Sales, by Country K Units (2018-2023)
  • Table 149. Europe Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 150. Europe Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 151. Europe Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 152. Germany Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 153. Germany Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 154. Germany Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 155. France Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 156. France Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 157. France Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 158. Italy Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 159. Italy Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 160. Italy Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 161. United Kingdom Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 162. United Kingdom Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 163. United Kingdom Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 164. Netherlands Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 165. Netherlands Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 166. Netherlands Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 167. Rest of Europe Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 168. Rest of Europe Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 169. Rest of Europe Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 170. MEA Adalimumab Biosimilar Sales, by Country K Units (2018-2023)
  • Table 171. MEA Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 172. MEA Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 173. MEA Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 174. Middle East Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 175. Middle East Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 176. Middle East Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 177. Africa Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 178. Africa Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 179. Africa Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 180. North America Adalimumab Biosimilar Sales, by Country K Units (2018-2023)
  • Table 181. North America Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 182. North America Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 183. North America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 184. United States Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 185. United States Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 186. United States Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 187. Canada Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 188. Canada Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 189. Canada Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 190. Mexico Adalimumab Biosimilar Sales, by Type K Units (2018-2023)
  • Table 191. Mexico Adalimumab Biosimilar Sales, by Application K Units (2018-2023)
  • Table 192. Mexico Adalimumab Biosimilar Sales, by Distribution Channel K Units (2018-2023)
  • Table 193. Adalimumab Biosimilar: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Adalimumab Biosimilar: by Type(USD Million)
  • Table 205. Adalimumab Biosimilar Exemptia , by Region USD Million (2025-2030)
  • Table 206. Adalimumab Biosimilar Adalirel , by Region USD Million (2025-2030)
  • Table 207. Adalimumab Biosimilar Cipleumab , by Region USD Million (2025-2030)
  • Table 208. Adalimumab Biosimilar Others , by Region USD Million (2025-2030)
  • Table 209. Adalimumab Biosimilar: by Application(USD Million)
  • Table 210. Adalimumab Biosimilar Psoriatic Arthritis , by Region USD Million (2025-2030)
  • Table 211. Adalimumab Biosimilar Rheumatoid Arthritis , by Region USD Million (2025-2030)
  • Table 212. Adalimumab Biosimilar Other , by Region USD Million (2025-2030)
  • Table 213. Adalimumab Biosimilar: by Distribution Channel(USD Million)
  • Table 214. Adalimumab Biosimilar Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 215. Adalimumab Biosimilar Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 216. Adalimumab Biosimilar Online Pharmacy , by Region USD Million (2025-2030)
  • Table 217. South America Adalimumab Biosimilar, by Country USD Million (2025-2030)
  • Table 218. South America Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 219. South America Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 220. South America Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 221. Brazil Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 222. Brazil Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 223. Brazil Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 224. Argentina Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 225. Argentina Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 226. Argentina Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 227. Rest of South America Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 228. Rest of South America Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 229. Rest of South America Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 230. Asia Pacific Adalimumab Biosimilar, by Country USD Million (2025-2030)
  • Table 231. Asia Pacific Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 232. Asia Pacific Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 233. Asia Pacific Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 234. China Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 235. China Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 236. China Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 237. Japan Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 238. Japan Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 239. Japan Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 240. India Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 241. India Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 242. India Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 243. South Korea Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 244. South Korea Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 245. South Korea Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 246. Taiwan Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 247. Taiwan Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 248. Taiwan Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 249. Australia Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 250. Australia Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 251. Australia Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 255. Europe Adalimumab Biosimilar, by Country USD Million (2025-2030)
  • Table 256. Europe Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 257. Europe Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 258. Europe Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 259. Germany Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 260. Germany Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 261. Germany Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 262. France Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 263. France Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 264. France Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 265. Italy Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 266. Italy Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 267. Italy Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 268. United Kingdom Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 269. United Kingdom Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 270. United Kingdom Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 271. Netherlands Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 272. Netherlands Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 273. Netherlands Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 274. Rest of Europe Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 275. Rest of Europe Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 276. Rest of Europe Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 277. MEA Adalimumab Biosimilar, by Country USD Million (2025-2030)
  • Table 278. MEA Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 279. MEA Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 280. MEA Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 281. Middle East Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 282. Middle East Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 283. Middle East Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 284. Africa Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 285. Africa Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 286. Africa Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 287. North America Adalimumab Biosimilar, by Country USD Million (2025-2030)
  • Table 288. North America Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 289. North America Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 290. North America Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 291. United States Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 292. United States Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 293. United States Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 294. Canada Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 295. Canada Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 296. Canada Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 297. Mexico Adalimumab Biosimilar, by Type USD Million (2025-2030)
  • Table 298. Mexico Adalimumab Biosimilar, by Application USD Million (2025-2030)
  • Table 299. Mexico Adalimumab Biosimilar, by Distribution Channel USD Million (2025-2030)
  • Table 300. Adalimumab Biosimilar Sales: by Type(K Units)
  • Table 301. Adalimumab Biosimilar Sales Exemptia , by Region K Units (2025-2030)
  • Table 302. Adalimumab Biosimilar Sales Adalirel , by Region K Units (2025-2030)
  • Table 303. Adalimumab Biosimilar Sales Cipleumab , by Region K Units (2025-2030)
  • Table 304. Adalimumab Biosimilar Sales Others , by Region K Units (2025-2030)
  • Table 305. Adalimumab Biosimilar Sales: by Application(K Units)
  • Table 306. Adalimumab Biosimilar Sales Psoriatic Arthritis , by Region K Units (2025-2030)
  • Table 307. Adalimumab Biosimilar Sales Rheumatoid Arthritis , by Region K Units (2025-2030)
  • Table 308. Adalimumab Biosimilar Sales Other , by Region K Units (2025-2030)
  • Table 309. Adalimumab Biosimilar Sales: by Distribution Channel(K Units)
  • Table 310. Adalimumab Biosimilar Sales Hospital Pharmacy , by Region K Units (2025-2030)
  • Table 311. Adalimumab Biosimilar Sales Retail Pharmacy , by Region K Units (2025-2030)
  • Table 312. Adalimumab Biosimilar Sales Online Pharmacy , by Region K Units (2025-2030)
  • Table 313. South America Adalimumab Biosimilar Sales, by Country K Units (2025-2030)
  • Table 314. South America Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 315. South America Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 316. South America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 317. Brazil Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 318. Brazil Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 319. Brazil Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 320. Argentina Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 321. Argentina Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 322. Argentina Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 323. Rest of South America Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 324. Rest of South America Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 325. Rest of South America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 326. Asia Pacific Adalimumab Biosimilar Sales, by Country K Units (2025-2030)
  • Table 327. Asia Pacific Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 328. Asia Pacific Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 329. Asia Pacific Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 330. China Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 331. China Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 332. China Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 333. Japan Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 334. Japan Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 335. Japan Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 336. India Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 337. India Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 338. India Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 339. South Korea Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 340. South Korea Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 341. South Korea Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 342. Taiwan Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 343. Taiwan Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 344. Taiwan Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 345. Australia Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 346. Australia Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 347. Australia Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 348. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 349. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 350. Rest of Asia-Pacific Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 351. Europe Adalimumab Biosimilar Sales, by Country K Units (2025-2030)
  • Table 352. Europe Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 353. Europe Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 354. Europe Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 355. Germany Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 356. Germany Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 357. Germany Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 358. France Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 359. France Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 360. France Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 361. Italy Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 362. Italy Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 363. Italy Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 364. United Kingdom Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 365. United Kingdom Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 366. United Kingdom Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 367. Netherlands Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 368. Netherlands Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 369. Netherlands Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 370. Rest of Europe Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 371. Rest of Europe Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 372. Rest of Europe Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 373. MEA Adalimumab Biosimilar Sales, by Country K Units (2025-2030)
  • Table 374. MEA Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 375. MEA Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 376. MEA Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 377. Middle East Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 378. Middle East Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 379. Middle East Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 380. Africa Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 381. Africa Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 382. Africa Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 383. North America Adalimumab Biosimilar Sales, by Country K Units (2025-2030)
  • Table 384. North America Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 385. North America Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 386. North America Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 387. United States Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 388. United States Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 389. United States Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 390. Canada Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 391. Canada Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 392. Canada Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 393. Mexico Adalimumab Biosimilar Sales, by Type K Units (2025-2030)
  • Table 394. Mexico Adalimumab Biosimilar Sales, by Application K Units (2025-2030)
  • Table 395. Mexico Adalimumab Biosimilar Sales, by Distribution Channel K Units (2025-2030)
  • Table 396. Adalimumab Biosimilar: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adalimumab Biosimilar: by Type USD Million (2018-2023)
  • Figure 5. Global Adalimumab Biosimilar: by Application USD Million (2018-2023)
  • Figure 6. Global Adalimumab Biosimilar: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Adalimumab Biosimilar Share (%), by Country
  • Figure 8. Asia Pacific Adalimumab Biosimilar Share (%), by Country
  • Figure 9. Europe Adalimumab Biosimilar Share (%), by Country
  • Figure 10. MEA Adalimumab Biosimilar Share (%), by Country
  • Figure 11. North America Adalimumab Biosimilar Share (%), by Country
  • Figure 12. Global Adalimumab Biosimilar: by Type K Units (2018-2023)
  • Figure 13. Global Adalimumab Biosimilar: by Application K Units (2018-2023)
  • Figure 14. Global Adalimumab Biosimilar: by Distribution Channel K Units (2018-2023)
  • Figure 15. South America Adalimumab Biosimilar Share (%), by Country
  • Figure 16. Asia Pacific Adalimumab Biosimilar Share (%), by Country
  • Figure 17. Europe Adalimumab Biosimilar Share (%), by Country
  • Figure 18. MEA Adalimumab Biosimilar Share (%), by Country
  • Figure 19. North America Adalimumab Biosimilar Share (%), by Country
  • Figure 20. Global Adalimumab Biosimilar: by Type USD/Units (2018-2023)
  • Figure 21. Global Adalimumab Biosimilar share by Players 2023 (%)
  • Figure 22. Global Adalimumab Biosimilar share by Players (Top 3) 2023(%)
  • Figure 23. Global Adalimumab Biosimilar share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. AET BioTech (Germany) Revenue, Net Income and Gross profit
  • Figure 26. AET BioTech (Germany) Revenue: by Geography 2023
  • Figure 27. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen (United States) Revenue: by Geography 2023
  • Figure 29. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 31. Coherus Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 32. Coherus Biosciences (United States) Revenue: by Geography 2023
  • Figure 33. Fujifilm Kyowa Kirin Biologics (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Fujifilm Kyowa Kirin Biologics (Japan) Revenue: by Geography 2023
  • Figure 35. LG Life Sciences (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. LG Life Sciences (South Korea) Revenue: by Geography 2023
  • Figure 37. Momenta Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 38. Momenta Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 39. Oncobiologics (New Jersey) Revenue, Net Income and Gross profit
  • Figure 40. Oncobiologics (New Jersey) Revenue: by Geography 2023
  • Figure 41. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer (United States) Revenue: by Geography 2023
  • Figure 43. Samsung Bioepsis (United States) Revenue, Net Income and Gross profit
  • Figure 44. Samsung Bioepsis (United States) Revenue: by Geography 2023
  • Figure 45. Global Adalimumab Biosimilar: by Type USD Million (2025-2030)
  • Figure 46. Global Adalimumab Biosimilar: by Application USD Million (2025-2030)
  • Figure 47. Global Adalimumab Biosimilar: by Distribution Channel USD Million (2025-2030)
  • Figure 48. South America Adalimumab Biosimilar Share (%), by Country
  • Figure 49. Asia Pacific Adalimumab Biosimilar Share (%), by Country
  • Figure 50. Europe Adalimumab Biosimilar Share (%), by Country
  • Figure 51. MEA Adalimumab Biosimilar Share (%), by Country
  • Figure 52. North America Adalimumab Biosimilar Share (%), by Country
  • Figure 53. Global Adalimumab Biosimilar: by Type K Units (2025-2030)
  • Figure 54. Global Adalimumab Biosimilar: by Application K Units (2025-2030)
  • Figure 55. Global Adalimumab Biosimilar: by Distribution Channel K Units (2025-2030)
  • Figure 56. South America Adalimumab Biosimilar Share (%), by Country
  • Figure 57. Asia Pacific Adalimumab Biosimilar Share (%), by Country
  • Figure 58. Europe Adalimumab Biosimilar Share (%), by Country
  • Figure 59. MEA Adalimumab Biosimilar Share (%), by Country
  • Figure 60. North America Adalimumab Biosimilar Share (%), by Country
  • Figure 61. Global Adalimumab Biosimilar: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • AET BioTech (Germany)
  • Amgen (United States)
  • Boehringer Ingelheim (Germany)
  • Coherus Biosciences (United States)
  • Fujifilm Kyowa Kirin Biologics (Japan)
  • LG Life Sciences (South Korea)
  • Momenta Pharmaceuticals (United States)
  • Oncobiologics (New Jersey)
  • Pfizer (United States)
  • Samsung Bioepsis (United States)
Additional players considered in the study are as follows:
Biocon (India) , Sandoz (Germany) , Zydus Cadila (India)
Select User Access Type

Key Highlights of Report


Feb 2024 218 Pages 75 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Adalimumab Biosimilar Quantitative research analysis
Global Adalimumab Biosimilar Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Adalimumab Biosimilar Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Adalimumab Biosimilar market is dominated by United States Players and may generate healthy valuation by 2030.
  • Rise in the Geriatric Population
  • Increasing Prevalence of Rheumatoid Arthritis
dominated the Adalimumab Biosimilar market. This is attributable to growing trend of "Rise in the Approvals of the New Biosimilars "

Know More About Global Adalimumab Biosimilar Report?

Have a Query? Click Here

Other Related Reports

serratiopeptidase Comprehensive Study by Application (Pharmaceutical & Diagnostics, Research/Biotechnology), Way of ordering (Walk-in, Online) Players and Region - Global Market Outlook to 2027
$ 3500
Iron Drugs Comprehensive Study by Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer Diseases, Others), End User...
$ 3350
Gravid Treatment Comprehensive Study by Type (Topical Products, Lasers, Microdermabrasion, Others), Application (Hospitals, Clinics, Specialty Dermatology Centres, Home-use, Others) Players and Regio...
$ 3500
Glaucoma Eye Drops Comprehensive Study by Type (Prostaglandin Analogs, Prostaglandin Analogs, Alpha Agonists, Carbonic Anhydrase Inhibitors (Cais), Rho Khinase Inhibitors, Combined Medications, Other...
$ 3650
Photosensitizer Drug Comprehensive Study by Type (Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlor...
$ 3750
Oral Antiseptics Comprehensive Study by Type (Chlorhexidine Gluconate, Essential Oils, Methyl Salicylate, Povidone-Iodine, Hydrogen Peroxide, Cetylpyridinium Chloride), Application (Dental Care, Oral...
$ 3650